Joint Clinical Trials Office

You are here

Phase 2 study of the combination of ibrutinib plus venetoclax in subjects with treatment-naive chronic lymphocytic leukemia / small lymphocytic lymphoma

Clinical Trial Details

This clinical trial is for men and women with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The results of clinical studies in previously untreated CLL have demonstrated major advances in therapy over the last decade; however, despite the impressive efficacy and safety results of single agent ibrutinib in previously untreated CLL subjects, complete responses remain low, and broader questions remain regarding the optimal duration of ibrutinib therapy. The Bcl-2 protein plays a significant role in the regulation of cell death in malignant cells. Overexpression of Bcl-2 family proteins is associated with tumor initiation, disease progression, and chemotherapy resistance. Venetoclax is a highly selective Bcl-2 family protein inhibitor that binds to Bcl-2 family proteins to potentially overcome resistance and induce cell death in cancer cells. Pre-clinical studies support combination with ibrutinib, and suggest potential enhanced activity vs each agent alone. This study has been designed to evaluate the efficacy and safety of the combination of ibrutinib and venetoclax in the treatment of previously-untreated CLL/SLL. The study will have a pre-randomization phase in which subjects will receive single-agent ibrutinib for 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles. Subsequently, subjects who achieve MRD-negative response will be randomized to receive blinded ibrutinib vs placebo. Subjects who achieve MRD-positive response will be randomized to continue the open-label combination vs continue ibrutinib only. Re-introduction of therapy is built into the study design for subjects who discontinue any of the study drugs as part of the randomization phase but may benefit from re-introduction. After discontinuing treatment, subjects will continue to be followed for survival status and subsequent anti-cancer therapy until study closure. 

Key Eligibility: 
  • Men and women age 18 and over 
  • Diagnosis of active CLL/SLL meeting at least one IWCLL criteria for requiring treatment 
  • Must not have received any prior therapy used for treatment of CLL or SLL 
  • Detailed eligibility will be reviewed when you contact the study team 

Contact

Rita Vaccaro
rig9021@med.cornell.edu
(212) 746 0702

Primary Investigator

John Allan, M.D.

Protocol ID(s)

Weill Cornell Medicine IRB #:

1611017717

ClinicalTrials.gov:

NCT02910583

Status:

Open to Enrollment

Age Group

Adult

Sponsor

Drug/Device

Drug

Study Type

Phase

2